Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

Hypothesis The use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.

Trial Details

NCT ID
NCT07299292
Phase
PHASE2
Sponsor
SMED Clinical Research
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Abiraterone 250 mg with food + prednisone
Locations (sample)
  • Buenos Aires, Argentina|-34.61315,-58.37723
  • Hermosillo, Spain|40.3349,-5.47372
  • Santa Cruz de la Sierra, Spain|39.33635,-5.84561

Key Eligibility Criteria

  • Age ≥18 years.
  • Histologically confirmed prostate adenocarcinoma.
  • Treated at Hospital Durand (Argentina) or Instituto Oncológico del Oriente Boliviano (Bolivia).
  • Indicated for hormonal intensification (high/very high risk candidates for RT, or mHSPC for doublet/triplet).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →